Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases

摘要

BackgroundHistorically, the beneficial effects of the nonsystemic oral agent rifaximin on various gastrointestinal (GI) disorders have been attributed to direct antibiotic activity on gut microbiota. However, data are accumulating to suggest that other nonantibacterial effects may be involved in rifaximin efficacy.